Literature DB >> 33606763

Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells.

Nawel Zaibi1, Pengyun Li1, Shang-Zhong Xu1,2.   

Abstract

Elevated reactive oxygen species (ROS) in type 2 diabetes cause cellular damage in many organs. Recently, the new class of glucose-lowering agents, SGLT-2 inhibitors, have been shown to reduce the risk of developing diabetic complications; however, the mechanisms of such beneficial effect are largely unknown. Here we aimed to investigate the effects of dapagliflozin on cell proliferation and cell death under oxidative stress conditions and explore its underlying mechanisms. Human proximal tubular cells (HK-2) were used. Cell growth and death were monitored by cell counting, water-soluble tetrazolium-1 (WST-1) and lactate dehydrogenase (LDH) assays, and flow cytometry. The cytosolic and mitochondrial (ROS) production was measured using fluorescent probes (H2DCFDA and MitoSOX) under normal and oxidative stress conditions mimicked by addition of H2O2. Intracellular Ca2+ dynamics was monitored by FlexStation 3 using cell-permeable Ca2+ dye Fura-PE3/AM. Dapagliflozin (0.1-10 μM) had no effect on HK-2 cell proliferation under normal conditions, but an inhibitory effect was seen at an extreme high concentration (100 μM). However, dapagliflozin at 0.1 to 5 μM showed remarkable protective effects against H2O2-induced cell injury via increasing the viable cell number at phase G0/G1. The elevated cytosolic and mitochondrial ROS under oxidative stress was significantly decreased by dapagliflozin. Dapagliflozin increased the basal intracellular [Ca2+]i in proximal tubular cells, but did not affect calcium release from endoplasmic reticulum and store-operated Ca2+ entry. The H2O2-sensitive TRPM2 channel seemed to be involved in the Ca2+ dynamics regulated by dapagliflozin. However, dapagliflozin had no direct effects on ORAI1, ORAI3, TRPC4 and TRPC5 channels. Our results suggest that dapagliflozin shows anti-oxidative properties by reducing cytosolic and mitochondrial ROS production and altering Ca2+ dynamics, and thus exerts its protective effects against cell damage under oxidative stress environment.

Entities:  

Year:  2021        PMID: 33606763     DOI: 10.1371/journal.pone.0247234

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

1.  Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes.

Authors:  Qianyi Luo; Sameer P Leley; Erika Bello; Hurshdeep Dhami; Deepa Mathew; Ashay Dilip Bhatwadekar
Journal:  BMJ Open Diabetes Res Care       Date:  2022-05

2.  Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury-Insight into Oxidative Injury/Inflammation/Apoptosis Modulation.

Authors:  Mohamed El-Sherbiny; Mohamed El-Shafey; Eman Said; Gehan Ahmed Shaker; Mohamed El-Dosoky; Hasnaa Ali Ebrahim; Sally Yussef Abed; Khalid M Ibraheem; Ahmed Mohsen Faheem; Muntazar AlMutawa; Bayader Alatawi; Nehal M Elsherbiny
Journal:  Life (Basel)       Date:  2022-05-21

Review 3.  Neuroprotective Effect of SGLT2 Inhibitors.

Authors:  Agnieszka Pawlos; Marlena Broncel; Ewelina Woźniak; Paulina Gorzelak-Pabiś
Journal:  Molecules       Date:  2021-11-28       Impact factor: 4.411

4.  Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction.

Authors:  Mei Ying Xuan; Shang Guo Piao; Jun Ding; Qi Yan Nan; Mei Hua Piao; Yu Ji Jiang; Hai Lan Zheng; Ji Zhe Jin; Can Li
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

Review 5.  Antioxidant Roles of SGLT2 Inhibitors in the Kidney.

Authors:  Carmen Llorens-Cebrià; Mireia Molina-Van den Bosch; Ander Vergara; Conxita Jacobs-Cachá; Maria José Soler
Journal:  Biomolecules       Date:  2022-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.